Navigation Links
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Date:11/10/2008

Complete Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher

Compared to Standard Chemotherapy

SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778) for patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) based on a preliminary intent to treat efficacy analysis. Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/uCR+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). CR/uCR and ORR were determined by an independent assessment panel that was blinded to the treatment assignments. The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised. Seventy-four percent of patients discontinued therapy for disease progression or death, the majority of which were in the standard chemotherapy control arm.

CTI plans to submit complete study data for presentation at a major scientific conference. CTI also intends to request a pre-NDA meeting with the FDA and expects to begin submission of a rolling New Drug Application (NDA) to the FDA in early 2009.

"This positive phase II
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
2. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
5. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
6. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
7. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
10. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
11. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Calif. , Sept. 17, 2014  Neuraltus Pharmaceuticals, ... Company,s Phase 2 clinical program of NP001 for the ... Gehrig,s disease) are being highlighted today in an ... ALS Research Group , being held in ... a  post hoc  analysis, administration of a high dose ...
(Date:9/17/2014)... 2014  Fortune Oil and Gas, Inc. (OTCPink:FOGC), today ... Manzo Pharmaceuticals, Inc. with the symbol (OTCPink : FOGCD). ... 17, 2014. Also taking effect today is a ten ... a pivotal event in the company,s progress according to ... could not proceed with the plan and still have ...
(Date:9/17/2014)... Pa. , Sept. 17, 2014  Auxilium Pharmaceuticals, ... company, today confirmed that Auxilium has received an unsolicited, ... ENDP ) to acquire all of the outstanding shares ... per share in cash and Endo stock, subject to ... the unsolicited, non-binding proposal that Auxilium received from Endo ...
Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7
... CHICAGO, June 9, 2011 Today a Cook County jury ... Chicago area man, Steven Johansen, who was administered Baxter blood ...  This was the first of hundreds of pending lawsuits on ... are pending in the Circuit Court of Cook County in ...
... Inc. today announced an agreement with the U.S. Department of ... the marketing and promotion of Keppra®, an anti-epileptic prescription medicine. ... this investigation occurred more than six years ago, and as ... United States since learning of the investigation in 2008. ...
Cached Medicine Technology:Nolan Law Group: Jury Finds Against Baxter Healthcare In Nation's First Contaminated Chinese Heparin Case 2UCB, Inc. Resolves Investigation of Past Keppra® Marketing and Promotional Activities 2
(Date:9/17/2014)... 17, 2014 The International Journal of Surgery ... its archive of previously published content: after 24 months published ... aim of the IJS is to improve surgical ... making these articles available to all will improve efforts to ... IJS said, "The journal has always been a great ...
(Date:9/17/2014)... In ongoing coverage of formulary exclusion ... (DBN) continues to find criticism surrounding the tactic. ... issue , CVS Caremark Corp. and Express Scripts ... cut more drugs than ever, but industry consultants ... likely to achieve. Despite finding the strategy problematic, ...
(Date:9/17/2014)... New York, N.Y. (PRWEB) September 17, 2014 ... for fans taking part in the fitness industry’s most ... in Las Vegas, NV. Two fans will each take ... fully loaded with Neon Sport supplements and gear. Fitmark ... booth during the Olympia Expo, September 19-20th. , ...
(Date:9/17/2014)... Mission Viejo, CA (PRWEB) September 17, 2014 ... meetings and events, announced today it has released ... engagement at large meetings and corporate events. The ... up, enhance presentation and document management capabilities and ... speaker and participants. , Lintelus Meeting 3.1 ...
(Date:9/17/2014)... 2014 Market Research Report on ... in-depth research report on the China DEHP Plasticizer ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2Health News:Lintelus Energizes Audiences with the Latest Version Of its Multi-Screen Interactive Software 2Health News:DEHP Plasticizer Industry & SiC Substrates Market Analysis For (NA, Asia, Europe & ROW) Research Now at DeepResearchReports.com 2Health News:DEHP Plasticizer Industry & SiC Substrates Market Analysis For (NA, Asia, Europe & ROW) Research Now at DeepResearchReports.com 3
... 2012) According to the results of a new ... Journal of the American College of Surgeons , ... disease and were not meaningfully involved in treatment discussions ... As a result, the study,s investigators determined that there ...
... News) -- A drug commonly used to treat patients with ... older than 40 years who have Down syndrome and Alzheimer,s, ... animal studies of the Alzheimer,s drug, memantine, showed promising results ... with Down syndrome aged 40 and older revealed the opposite, ...
... January/February issue of Annals takes an up-close look ... a single individual, a phenomenon that is growing at an ... is estimated by the year 2020, 25 percent of the ... costs for managing these conditions will reach $1.07 trillion. In ...
... injury (AKI) has severe consequences, with a 25 to 80 ... to diagnose AKI using a urine test, enabling emergency departments ... the hospital. The study will be published online on January ... of Cardiology. Physicians typically measure a patient,s creatinine ...
... Steven Reinberg HealthDay Reporter , MONDAY, Jan. 9 ... heartbreaking grief, suggests new research that finds losing a loved ... a day of a significant other,s death, heart attack risk ... at data on nearly 2,000 heart attack patients. And within ...
... risk of suffering a heart attack increases by approximately 21 ... one, according to a study lead by researchers at Beth ... 9 online in the journal Circulation found the ... the first week after the death of a loved one, ...
Cached Medicine News:Health News:Early-stage breast cancer patients lack knowledge; may not receive treatment they prefer 2Health News:Early-stage breast cancer patients lack knowledge; may not receive treatment they prefer 3Health News:Alzheimer's Med Seems Ineffective in Those With Down Syndrome 2Health News:January/February 2012 Annals of Family Medicine 2Health News:January/February 2012 Annals of Family Medicine 3Health News:January/February 2012 Annals of Family Medicine 4Health News:January/February 2012 Annals of Family Medicine 5Health News:January/February 2012 Annals of Family Medicine 6Health News:January/February 2012 Annals of Family Medicine 7Health News:January/February 2012 Annals of Family Medicine 8Health News:January/February 2012 Annals of Family Medicine 9Health News:Biomarkers identify acute kidney injury in emergency patients 2Health News:Grief Is a Real Heartbreaker, Study Finds 2Health News:Grief Is a Real Heartbreaker, Study Finds 3Health News:Heart attack risk rises after loss of loved one 2
... protection, our conventional aprons are ... sturdy 2 webbed straps that ... hook fasteners. The straps can ... the apron. Our conventional apron ...
Unshielded...
... Triage BNP Test is the first ... measuring B-type natriuretic peptide (BNP) ,Cardiac ... in response to ventricular volume expansion ... of ventricular systolic and diastolic dysfunction. ...
... MOST Options System is designed to ... of the knee or hip to ... provides the potential for restoration of ... the requirements of a rotating hinge ...
Medicine Products: